The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Comparison of pharmacokinetics and pharmacodynamics of BCD-020 with innovator rituximab in patients with indolent non-Hodgkin lymphoma.
I. Poddubnaya
No relevant relationships to disclose
L. Babicheva
No relevant relationships to disclose
K. Kaplanov
No relevant relationships to disclose
Andrey Zaritskey
No relevant relationships to disclose
E. Volodicheva
No relevant relationships to disclose
S. Alexeev
No relevant relationships to disclose
A. Loginov
No relevant relationships to disclose
R. Orlova
No relevant relationships to disclose
V. Dvornichenko
No relevant relationships to disclose
Oleg Gladkov
No relevant relationships to disclose
M. Kosinova
No relevant relationships to disclose
O. Serduk
No relevant relationships to disclose
V. Milovanov
No relevant relationships to disclose
A. Myasnikov
No relevant relationships to disclose
Attili Venkatasatya Suresh
No relevant relationships to disclose
Minish Jain
No relevant relationships to disclose
S. Patil
No relevant relationships to disclose
Senthil Jagannathan Rajappa
No relevant relationships to disclose
R. Ivanov
No relevant relationships to disclose
E. Chernyaeva
No relevant relationships to disclose